Table 1 Reports in the literature of oral lichenoid lesions in association with the same drugs used by the two patients reported in the present study

Kuten-Shorrer [6]

43/F

Rituximab

(750mg/m²)

Three months after the 4th dose

Ulcerated and reticular lesions ranging from 0.5 to 4.0 cm, distributed bilaterally and symmetrically on the buccal mucosa, upper labial mucosa, and dorsal and ventral of the tongue

No

Topical dexamethasone solution (5 mg per 5 mL), twice daily, and 40 mg prednisone for 7 days

Complete resolution of the lesions 9-month after the treatment

Giudice et al. [5]

40/F

Rituximab (375 mg)

After the 5th dose

Ulcerated and reticular lesions on buccal mucosa (bilateral and symmetrical) and on the right border of the tongue

Skin

Intralesional injections of 0.5 mL triamcinolone acetonide (Kenacort 40 mg/mL) and systemic corticosteroid

At 6-month follow-up, 9 months after rituximab withdrawal, oral symptomatology did not relapse; skin lesions and joint pain had autonomously healed while oral ulcers did not completely disappear

Kusano et al. [29]

65/M

Bendamustine and rituximab

After the 4th week of treatment

Bullous lesions on lip and oral cavity

Skin, eye, genital and nasal mucosa

Prednisone 5 mg daily

Oral mucosal lesions were intractable after 4-months of treatment

Bronny and Thies [17]

59/M

Sulfamethoxazole

Information not available

Ulcerated lesions (1 cm x 5 mm) near the right lip commissure and left buccal mucosa distal to the commissure. White striae and papules radiated from these ulcers

No

A 1- week course of systemic methylprednisolone decreasing-dosage therapy and viscous lidocaine for symptomatic relief

After one week of treatment, oral lesions were still present although greatly improved